China’s First Original Radiopharmaceutical Approved, Local Innovation Takes on Multinational Giants

China’s locally generated innovative force is shaking up the playing field dominated by multinational giants such as Novartis, Bayer, and AstraZeneca in the field of radiopharmaceuticals. Analyzing the approval, a healthcare industry analyst stated, ‘This event marks China’s nuclear medicine drugs stepping out of the comfort zone of imitation and entering a new chapter of original innovation, leading the nuclear pharmaceutical market from a state of monopoly by a few players to a stage of innovative differentiation.’ The Chinese industrial capital and scientific spirit are attempting to rewrite the rules of the game amidst fierce competition in the ‘nuclear’ race….